Analysed ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) News Sources
Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
21-07-2026
yahoo.com
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
23-07-2026
yahoo.com
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
23-07-2026
trefis.com
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
27-07-2026
yahoo.com
Unlocking Q2 Potential of Alnylam (ALNY): Exploring Wall Street Estimates for Key Metrics
28-07-2026
yahoo.com
Alnylam (ALNY) Is Up 6.3% After Showcasing New Alzheimer’s RNAi Data And $1B-Plus Quarterly Revenue
29-07-2026
yahoo.com
Alnylam Pharmaceuticals (ALNY) Could Be 34% Undervalued After Alzheimer’s Pipeline Update
29-07-2026
yahoo.com
What is the current price of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)?
The current price of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) is $207.03.
ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) since the previous trading day is $-79.59.
ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) since the previous trading day is -27.7685%.
What is the most recent average sentiment score for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)?
The most recent average sentiment score for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)?
The most recent sentiment for ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ) is .
SEC-8K** Filing Available For ALNYLAM PHARMACEUTICALS INC (ALNY:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.